bispecific antibody therapy (cancer)

未知生产厂商

专利

每项发明一条，涵盖美国、欧洲、PCT 与中国的同族专利。

ANTI-NKG2A ANTIBODIES AND USES THEREOF
申请人: BRISTOL MYERS SQUIBB CO优先权: 2018
CN
EP
US
WO
10 件公开
EGFR X CD28 MULTISPECIFIC ANTIBODIES
申请人: REGENERON PHARMA优先权: 2019
CN
EP
US
WO
7 件公开
METHODS OF TREATING CANCER WITH A COMBINATION OF A TAAXCD3 BISPECIFIC ANTIBODY AND A TARGETED IMMUNOCYTOKINE
申请人: REGENERON PHARMA优先权: 2023
CN
EP
US
WO
4 件公开
ANTI-PD-1 ANTIBODY AND USES THEREOF
申请人: EUTILEX CO LTD优先权: 2020
CN
EP
US
3 件公开
Dosing Regimen for Therapies Comprising Bispecific Anti-EGFR/C-Met Antibodies
申请人: JANSSEN BIOTECH INC优先权: 2023
CN
US
3 件公开
Therapeutic antibodies and their uses
申请人: PFIZER优先权: 2015
CN
3 件公开
AFFINITY MATURED C-MET ANTIBODIES
申请人: MERCK PATENT GMBH优先权: 2015
CN
EP
2 件公开
DOSING REGIMEN FOR THERAPIES COMPRISING BISPECIFIC ANTIEGFR/C-MET ANTIBODIES
申请人: JANSSEN BIOTECH INC优先权: 2023
EP
WO
2 件公开
METHODS FOR THE DETECTION AND TREATMENT OF RESISTANT CANCERS CO-EXPRESSING ALPP AND/OR ALPG/ALPPL2
申请人: UNIV TEXAS优先权: 2023
EP
WO
2 件公开
METHODS FOR TREATING MULTIPLE MYELOMA WITH CAR-T CELLS AND BISPECIFIC ANTIBODIES
申请人: JANSSEN BIOTECH INC优先权: 2024
US
WO
2 件公开